MLC1501 Study Assessing Efficacy in Post STrOke Subjects With mOtor Deficits

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 303 participants.

Also called NCT05289947

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 303 participants (enrolled count) (from the registry)
Sponsor
Moleac Pte Ltd. (from the registry)
Registry
  • NCT NCT05289947
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Philippines, Singapore (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05289947. Randomized; quadruple masking; primary purpose treatment. Start 2023-07-21 (actual); primary completion 2025-07-18 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
MLC1501 Study Assessing Efficacy in Post STrOke Subjects With mOtor Deficits
Acronym
MAESTOSO
Condition
Stroke
Condition
Stroke, Ischemic
Condition
Strokes Thrombotic
Condition
Stroke Sequelae
Condition
Stroke, Cardiovascular
Condition
Stroke, Embolic
Condition
Stroke, Cryptogenic
Intervention (Other)
Placebo
Intervention (Drug)
MLC1501
Lead sponsor
Moleac Pte Ltd. (class: industry)

Record details

Record id
cardio:ct-nct05289947
Content hash
ce86c54ecad0bb8d21489ce726e183c9919fedfd7c42f775a673e656a5bae9ea